litlas
Log inCreate account

PierFranco Conte

Active 1986–2025

Also published as
Pierfranco Conte
196
Papers
37,062
Citations
95
h-index
193
i10-index

Citations

Citations per year for PierFranco Conte1964: 2 citations1982: 1 citations1987: 5 citations1989: 3 citations1990: 4 citations1991: 4 citations1992: 4 citations1993: 12 citations1994: 4 citations1995: 10 citations1996: 13 citations1997: 19 citations1998: 46 citations1999: 26 citations2000: 36 citations2001: 60 citations2002: 59 citations2003: 57 citations2004: 76 citations2005: 77 citations2006: 87 citations2007: 102 citations2008: 86 citations2009: 107 citations2010: 118 citations2011: 128 citations2012: 128 citations2013: 141 citations2014: 107 citations2015: 117 citations2016: 150 citations2017: 195 citations2018: 268 citations2019: 1,011 citations2020: 1,496 citations2021: 1,710 citations2022: 1,469 citations2023: 1,299 citations2024: 1,830 citations2025: 898 citations2026: 28 citations1965–1981: no citations, so these years are not shown1983–1986: no citations, so these years are not shown1988: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,660 citing papers, 22.5% of this breakdownChina: 1,507 citing papers, 9.3% of this breakdownItaly: 1,348 citing papers, 8.3% of this breakdownUnited Kingdom: 980 citing papers, 6% of this breakdownGermany: 801 citing papers, 4.9% of this breakdownSpain: 756 citing papers, 4.6% of this breakdownFrance: 751 citing papers, 4.6% of this breakdownCanada: 528 citing papers, 3.2% of this breakdownJapan: 524 citing papers, 3.2% of this breakdownAustralia: 414 citing papers, 2.5% of this breakdownBelgium: 408 citing papers, 2.5% of this breakdownNetherlands: 396 citing papers, 2.4% of this breakdown
0%22.5%Other 26%

Institutions

Fields

  • Medicine71.6%
  • Biochemistry, Genetics and Molecular Biology23.1%
  • Immunology and Microbiology1.2%
  • Computer Science0.7%
  • Engineering0.6%
  • Materials Science0.6%
  • Other2.2%

Topics

  • Advanced Breast Cancer Therapies7.3%
  • HER2/EGFR in Cancer Research6.1%
  • Breast Cancer Treatment Studies5.2%
  • Cancer Immunotherapy and Biomarkers4%
  • PARP inhibition in cancer therapy3.3%
  • Cancer Genomics and Diagnostics3.3%
  • Other70.8%

Coauthors

All papers

Open in search
  1. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Authors: Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, PierFranco Conte, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric - New England Journal of Medicine 2019 cited by 2,572

  2. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

    Authors: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Wěi Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, PierFranco Conte - New England Journal of Medicine 2017 cited by 3,214

  3. Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    Authors: Gabriel N. Hortobagyi, Salomon M. Stemmer, Howard A. Burris, Yoon-Sim Yap, Gabe S. Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P. Winer, Wolfgang Janni, Pierfranco Conte, David A. Cameron, Fabrice André, Carlos L. Arteaga, Juan P. Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy - New England Journal of Medicine 2022 cited by 713

  4. openalex_id:w4221085715

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Lowell L. Hart, Mario Campone, Katarína Petráková, Eric P. Winer, Wolfgang Janni, PierFranco Conte, David Cameron, Fabrice André, Carlos L. Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Joyce O’Shaughnessy cited by 579

  5. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 cited by 2,009

  6. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

    Authors: George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, Eva‐Maria Grischke, PierFranco Conte, Yi Lu, Susana Barriga, Karla Hurt, Martin Frenzel, Stephen Johnston, Antonio Llombart‐Cussac - JAMA Oncology 2019 cited by 987

  7. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Authors: Paul K. Paik, Enriqueta Felip, Rémi Veillon, Hiroshi Sakai, Alexis B. Cortot, Marina Chiara Garassino, Julien Mazières, Santiago Viteri, Hélène Senellart, Jan P. van Meerbeeck, Jo Raskin, Niels Reinmuth, PierFranco Conte, Dariusz M. Kowalski, Byoung Chul Cho, Jyoti D. Patel, Leora Horn, Frank Griesinger, Ji‐Youn Han, Young‐Chul Kim, Gee‐Chen Chang, Chen‐Liang Tsai, James Chih‐Hsin Yang, Yuh-Min Chen, Egbert F. Smit, Anthonie J. van der Wekken, Terufumi Kato, Dilafruz Juraeva, Christopher Stroh, Rolf Bruns, Josef Straub, Andreas Johne, J. Scheele, John V. Heymach, Xiuning Le - New England Journal of Medicine 2020 cited by 854

  8. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    Authors: Fabrice André, Eva Ciruelos, Dejan Juric, Sibylle Loibl, Mario Campone, Ingrid A. Mayer, Gábor Rubovszky, Toshinari Yamashita, Bella Kaufman, Yen‐Shen Lu, Kenichi Inoue, Zsuzsanna Pápai, Masato Takahashi, Farhat Ghaznawi, David Mills, Mathilde Kaper, Michelle C. Miller, PierFranco Conte, Hiroji Iwata, Hope S. Rugo - Annals of Oncology 2020 cited by 599

  9. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

    Authors: Gabriel N. Hortobágyi, Salomon M. Stemmer, H.A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, M. Campone, Katarína Petráková, Kimberly Blackwell, Eric P. Winer, W Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, S. Mondal, Fei Su, Marshall G. Miller, Mohamed Elmeliegy, Caroline Germa, Joyce O’Shaughnessy - Annals of Oncology 2018 cited by 868

  10. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Authors: Mark E. Robson, Nadine Tung, PierFranco Conte, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Norikazu Masuda, Suzette Delaloge, W. Li, Anne Armstrong, Weiwen Wu, Carsten Goessl, Sarah Runswick, Susan M. Domchek - Annals of Oncology 2019 cited by 760

  11. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

    Authors: Hans von der Maase, Steen Werner Hansen, J.T. Roberts, Luigi Dogliotti, T. Oliver, Malcolm J. Moore, I. Bodrogi, Peter Albers, Alexander Knuth, Christian Lippert, Pierre Kerbrat, Pedro Sánchez‐Rovira, Peter Wersäll, Simon Cleall, D. Roychowdhury, Irene Tomlin, Carla Visseren‐Grul, PierFranco Conte - Journal of Clinical Oncology 2000 cited by 2,286

  12. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

    Authors: Aleix Prat, Valentina Guarneri, Tomás Pascual, Fara Brasó‐Maristany, Esther Sanfeliu, Laia Paré, Francesco Schettini, Débora Martínez, Pedro Jares, Gaia Griguolo, Maria Vittoria Dieci, Javier Cortés, Antonio Llombart‐Cussac, Benedetta Conte, Mercedes Marín‐Aguilera, Núria Chic, Joan Anton Puig‐Butillé, Antonio Martı́nez, Patricia Galván, Yi‐Hsuan Tsai, Blanca González‐Farré, Áurea Mira, Ana Vivancos, Patricia Villagrasa, Joel S. Parker, PierFranco Conte, Charles M. Perou - EBioMedicine 2022 cited by 145

  13. Evolution of HER2-low expression from primary to recurrent breast cancer

    Authors: Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Maria Vernaci, Ottavia Amato, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci - npj Breast Cancer 2021 cited by 226

  14. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

    Authors: PierFranco Conte, P.A. Ascierto, Giorgio Patelli, Romano Danesi, Angelo Vanzulli, Fabio Sandomenico, Paolo Tarsia, Anna Maria Cattelan, Alessia Comes, Michelino De Laurentiis, Alfredo Falcone, Daniele Regge, Luca Richeldi, Salvatore Siena - ESMO Open 2022 cited by 214

  15. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management

    Authors: Sandra M. Swain, Mizuki Nishino, Lisa Lancaster, Bob T. Li, Andrew G. Nicholson, Brian J. Bartholmai, Jarushka Naidoo, Eva Schumacher-Wulf, Kohei Shitara, Junji Tsurutani, PierFranco Conte, Terufumi Kato, Fabrice André, Charles A. Powell - Cancer Treatment Reviews 2022 cited by 167

  16. Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Authors: Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, PierFranco Conte, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, S Stanzel, Alexander Strasak, Monika Patre, Paul Ellis - Journal of Clinical Oncology 2017 cited by 413

  17. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

    Authors: Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, PierFranco Conte, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders - Clinical Cancer Research 2020 cited by 198

  18. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

    Authors: Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus, Binghe Xu, Susan M. Domchek, Norikazu Masuda, Suzette Delaloge, Nadine Tung, Anne Armstrong, Mike Dymond, Anitra Fielding, A. Allen, PierFranco Conte - European Journal of Cancer 2023 cited by 111

  19. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

    Authors: Hope S. Rugo, Fabrice André, Toshinari Yamashita, Humberto Cerda, I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos, Hiroji Iwata, PierFranco Conte, Mario Campone, C. Wilke, David Mills, Agnes Lteif, Michelle C. Miller, Fiorenza Gaudenzi, Sibylle Loibl - Annals of Oncology 2020 cited by 187

  20. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    Authors: Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, Marc Espié, Sibel Blau, Antoinette R. Tan, Steven J. Isakoff, Mafalda Oliveira, Cristina Saura, Matthew Wongchenko, Amy V. Kapp, Wai Yee Chan, Stina Mui Singel, Daniel Maslyar, José Baselga, Sungbae Kim, Keun Seok Lee, Seock‐Ah Im, Marc Espié, Hwei-Chung Wang, Sibel Blau, Rebecca Dent, Antoinette R. Tan, Joohyuk Sohn, Michelino De Laurentiis, Laura García‐Estévez, Chiun‐Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva-Vázquez, PierFranco Conte, Shaker R. Dakhil, Marc Debled, Antonio González-Martı́n, Sara A. Hurvitz, Jee Hyun Kim, Christelle Lévy, Mafalda Oliveira, Pedro Sánchez‐Rovira, Jae Hong Seo, Vicente Valero, Gregory A. Vidal, Andrea Wong, Mary Ann Allison, Robert A. Figlin, David Chan, Shin‐Cheh Chen, Yen‐Hsun Chen, Melody Cobleigh, Filippo de Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven J. Isakoff, William Lawler, Álvaro Montaño, Mohamad Salkini, L. Seigel - The Lancet Oncology 2017 cited by 474

  21. Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial

    Authors: Maria Vittoria Dieci, Valentina Guarneri, Anna Tosi, Giancarlo Bisagni, Antonino Musolino, Simon Spazzapan, Gabriella Moretti, Grazia Maria Vernaci, Gaia Griguolo, Tommaso Giarratano, Loredana Urso, Francesca Schiavi, Claudia Pinato, Giovanna Magni, Marcello Mele, Gian Luca De Salvo, Antonio Rosato, PierFranco Conte - Clinical Cancer Research 2021 cited by 115

  22. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

    Authors: Francesco Schettini, Tomás Pascual, Benedetta Conte, Núria Chic, Fara Brasó‐Maristany, Patricia Galván, Olga Martínez‐Sáez, Bárbara Adamo, María Vidal, Montserrat Muñoz-Mateu, Aranzazu Fernández-Martínez, Carla Rognoni, Gaia Griguolo, Valentina Guarneri, PierFranco Conte, Mariavittoria Locci, Jan C. Brase, Blanca González‐Farré, Patricia Villagrasa, Sabino De Placido, Rachel Schiff, Jamunarani Veeraraghavan, Mothaffar F. Rimawi, C. Kent Osborne, Sònia Pernas, Charles M. Perou, Lisa A. Carey, Aleix Prat - Cancer Treatment Reviews 2020 cited by 185

  23. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer

    Authors: Marion van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E. Geyer, Luca Gianni, Andreas Schneeweiß, PierFranco Conte, Martine Piccart, Hervé Bonnefoi, Christian Jackisch, Valentina Nekljudova, Gong Tang, Pinuccia Valagussa, Colin Neate, Richard D. Gelber, Coralie Poncet, Pierre Squifflet, Everardo D. Saad, Dominik Heinzmann, Carsten Denkert, Priya Rastogi, Javier Cortés, Valentina Guarneri, Evandro de Azambuja, David Cameron, Gustavo Ismael, Norman Wolmark, Patricia Cortazar, on behalf of the CTNeoBC project - Journal of Clinical Oncology 2023 cited by 96

  24. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

    Authors: Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso, Ilaria Attili, Paola Del Bianco, Giulia Pasello, Valentina Guarneri, Giuseppe Aprile, PierFranco Conte, Laura Bonanno - The Oncologist 2019 cited by 228